# A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer

> **NCT00664170** · PHASE1 · COMPLETED · sponsor: **Mast Therapeutics, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** ANX-514
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00664170
- **Lead sponsor:** Mast Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2009-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00664170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00664170, "A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00664170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*